Robeco Institutional Asset Management B.V. Cuts Stake in Insulet Co. (NASDAQ:PODD)

Robeco Institutional Asset Management B.V. reduced its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 9.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,049 shares of the medical instruments supplier's stock after selling 2,624 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Insulet were worth $5,597,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Diversified Trust Co raised its holdings in Insulet by 90.9% during the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier's stock worth $1,842,000 after acquiring an additional 4,348 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Insulet by 349.3% during the 1st quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier's stock worth $5,069,000 after buying an additional 22,993 shares during the last quarter. Intech Investment Management LLC raised its holdings in Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier's stock valued at $1,140,000 after acquiring an additional 3,539 shares during the period. Natixis acquired a new position in shares of Insulet in the first quarter valued at approximately $3,610,000. Finally, Seven Eight Capital LP bought a new position in shares of Insulet during the first quarter worth approximately $1,418,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. UBS Group lifted their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research note on Friday, August 9th. Barclays lifted their price target on Insulet from $200.00 to $220.00 and gave the company an "equal weight" rating in a research note on Monday, August 12th. Citigroup upped their price objective on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a research report on Tuesday, October 1st. BTIG Research raised their price target on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research note on Friday. Finally, Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat.com, Insulet has an average rating of "Moderate Buy" and a consensus price target of $246.80.

Insulet Stock Up 9.4 %

Insulet stock traded up $23.02 during midday trading on Friday, hitting $268.00. 1,582,981 shares of the stock were exchanged, compared to its average volume of 782,076. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The stock has a market capitalization of $18.79 billion, a price-to-earnings ratio of 48.73, a price-to-earnings-growth ratio of 4.47 and a beta of 1.22. Insulet Co. has a 52-week low of $151.56 and a 52-week high of $275.52. The business's 50-day moving average price is $232.01 and its 200-day moving average price is $203.96.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business's revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.38 earnings per share. On average, research analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.